Ace Alzheimer Center Barcelona’s Post

Alzheimer Disease Biomarkers: Moving from CSF to Plasma for Reliable Detection of Amyloid and tau Pathology https://lnkd.in/g5sTqhhs

Unlocking the Future of Alzheimer’s Treatment: A Must-Read Blog by colleagues at Worldwide Clinical Trials. Alzheimer’s disease remains a formidable challenge in medicine due to its complex nature and the critical need for early detection. This blog explores groundbreaking innovations in AD therapeutics, including the integration of fluid and imaging biomarkers that are reshaping clinical trial designs. These advancements could enhance treatment windows and allow for FDA accelerated approvals. Dive into the latest breakthroughs, such as the FDA’s regulatory adaptations, providing a comprehensive overview of the current landscape and future directions in AD research. Read the full article here. #AlzheimersResearch #Biomarkers #ClinicalTrials #FDA

Blood-based biomarker testing for Alzheimer’s 😍 Labcorp and Quest Diagnostics have both announced the availability of blood-based biomarker testing for Alzheimer’s disease, one which detects glial fibrillary acidic protein and another for phosphorylated tau. According to a release from Labcorp, the glial fibrillary acidic protein (GFAP) test utilizes highly sensitive immunoassay technology to measure levels of the biomarker — which can be found within astrocytes, the brain's support cells — from a simple blood draw that can be conducted both inside and outside the clinical setting. The assay offers physicians a more efficient and rapid means to assess presence and progression of other neurodegenerative diseases such as multiple sclerosis, glioblastoma and traumatic brain injury. Labcorp and Quest Diagnostics announced the addition of blood-based biomarker tests for the early detection of Alzheimer’s disease and other neurodegenerative conditions. Image: Adobe Stock "The introduction of the GFAP biomarker test marks a significant milestone for Labcorp, extending our leadership in the rapidly accelerating field of blood-based biomarkers for neurodegenerative diseases,” Brian Caveney, MD, Labcorp's chief medical and scientific officer, said in the release. "The breadth of our portfolio reflects our commitment to providing physicians with cutting-edge technology for the evaluation and treatment of neurodegeneration to enhance and improve patient care." Continue reading on flipboard.com

A study recently published in Nature, demonstrating plasma biomarkers including Ab42, p-tau181 and NfL are useful in predicting AD 8 years previous to clinical onset. Please do get in contact if you wish to find out more about how the ultra-sensitive SIMOA technology, is capable of detecting low level of biomarkers to predict and prevent the onset of diseases in the areas of Neurology, Oncology, Inflammation, Cardiology and Infectious diseases. https://lnkd.in/eXCYamjJ #Alzheimers #EarlyDiagnosis #Biomarkers

Exciting news in Alzheimer's research! Revolutionary blood biomarkers are changing the game in diagnostics and treatment. Traditional methods like imaging and cerebrospinal fluid testing often pose challenges due to their invasiveness. Enter Mayo Clinical Laboratories' latest breakthrough: a noninvasive plasma biomarker assay, discussed by Dr. Alicia Algeciras-Schimnich in a recent episode of "Answers From the Lab" podcast. Tailored for individuals aged 50 and above, this assay offers accessible and accurate testing without invasive procedures. Dr. Algeciras-Schimnich emphasizes the significance of this advancement in evaluating mild cognitive impairment and determining eligibility for disease-modifying therapies. Clinically validated through rigorous Mayo Clinic research, this immunoassay identifies phosphorylated Tau 217 (p-Tau217) with an impressive sensitivity of 92% and specificity of 96%. With disease-modifying therapies now available, biomarker testing for Alzheimer's is becoming essential in clinical evaluations, offering rapid and scalable solutions for detecting amyloid pathology. Excited to learn more? Tune in to the podcast for a deep dive into Mayo Clinic Laboratories' cutting-edge plasma biomarker testing for Alzheimer's disease (https://lnkd.in/dY_HkCU5)!  #Mayocliniclaboratory #Alzheimers #AD #MedicalInnovation #BloodTest #ResearchBreakthrough

Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies. Blood phosphorylated tau (p-tau) biomarkers, at differing sites, demonstrate high accuracy to detect Alzheimerʼs disease (AD). However, knowledge on the optimal marker for disease identification across the AD continuum and the link to pathology is limited. This is partly due to heterogeneity in analytical methods. In this study, we employed an immunoprecipitation mass spectrometry method to simultaneously quantify six phosphorylated (p-tau181, p-tau199, p-tau202, p-tau205, p-tau217 and p-tau231) and two non-phosphorylated plasma tau peptides in a total of 214 participants from the Paris Lariboisière and Translational Biomarkers of Aging and Dementia cohorts. Our results indicate that p-tau217, p-tau231 and p-tau205 are the plasma tau forms that best reflect AD-related brain changes, although with distinct emergences along the disease course and correlations with AD features—amyloid and tau. These findings support the differential association of blood p-tau variants with AD pathology, and our method offers a potential tool for disease staging in clinical trials. https://lnkd.in/eF3eY7C7

Exciting international research reveals the power of next-generation sequencing (NGS) in diagnosing complex cardiac conditions like hypertrophic cardiomyopathy (HCM) and phenocopies. 🧬 The study explores a 17-gene NGS panel's effectiveness in identifying genetic causes of HCM, including treatable conditions like transthyretin cardiac amyloidosis (ATTR-CA) and Fabry disease (FD). 💡 Discover how early diagnosis with NGS can optimize patient care and outcomes. 🌍 Read more about this groundbreaking study: https://lnkd.in/dzCRRnMh   #NGS #Cardiology #HypertrophicCardiomyopathy #Genetics #MedicalResearch #HealthcareInnovation

📃Scientific paper: Parkinson's Disease Modification Through Abl Kinase Inhibition: An Opportunity Abstract: Parkinson's disease (PD) is the second most prevalent neurodegenerative disease of the central nervous system, with an estimated 5 000 000 cases worldwide. Historically characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta, PD pathology is now known to be widespread and to affect serotonin, cholinergic and norepinephrine neurons as well as nerve cells in the olfactory system, cerebral hemisphere, brain stem, spinal cord, and peripheral autonomic nervous system. PD pathology is characterized by the accumulation of misfolded α‐synuclein, which is thought to play a critical role in the etiopathogenesis of the disease. Animal models of PD suggest that activation of the Abelson tyrosine kinase (c‐Abl) plays an essential role in the initiation and progression of α‐synuclein pathology and neurodegeneration. These studies demonstrate that internalization of misfolded α‐synuclein activates c‐Abl, which phosphorylates α‐synuclein and promotes α‐synuclein pathology within the affected neurons. Additionally, c‐Abl inactivates parkin, disrupting mitochondrial quality control and biogenesis, promoting neurodegeneration. Post‐mortem studies of PD patients demonstrate increased levels of tyrosine phosphorylated α‐synuclein, consistent with the activation of c‐Abl in human disease. Although the c‐Abl inhibitor nilotinib failed to demonstrate clinical benefit in two double‐blind trials, novel c‐Abl inhibitors have been developed that accum... Continued on ES/IODE ➡️ https://etcse.fr/qdOUM ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

The Alzheimer’s disease research community have been trying to identify predictive biomarkers for early detection of neurodegeneration for many years. Here, the authors report that, in a multicenter human cohort, brain-derived phosphorylated-tau (BD-tau - a structural component of axons) in blood increases concomitant with Aβ and neurodegenerative abnormalities detected in cerebrospinal fluid. They demonstrate that blood-based BD-tau is a biomarker for identifying Aβ-positive individuals at risk of short-term cognitive decline and atrophy. This biomarker will be useful for future clinical trials, especially those testing anti-Aβ therapies. Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer’s disease https://lnkd.in/gXMnsYzh